Trial Profile
Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor, in Allergic Asthmatics
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jun 2011
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- 15 Jun 2011 New trial record